Cytokinetics, Incorporated
CYTKHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Cytokinetics, Incorporated focuses on Biotechnology services and products. Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating. The company carries a $10.89B market cap, placing it firmly in the large-cap category. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Market Cap
$10.89B
Beta
0.42
P/E (TTM)
—
P/E (Fwd)
-17.11
EPS (TTM)
$-6.83
EPS (Fwd)
$-4.69
ROE
—
ROA
-31.5%
Cash
$818.6M
Total Debt
$1.44B
Free CF
-$381.1M
52W Change
115.4%
Annual Financials
Cash vs Debt
Cytokinetics, Incorporated carries $1.44B in total debt against $818.6M in cash reserves — debt is roughly 1.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$381.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has been relatively flat, moving from $94.6M (2022) to $88.0M (2025).
The relatively low beta of 0.42 suggests CYTK is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cytokinetics, Incorporated and its sector.